EPL share price is approaching a decisive juncture, both fundamentally and technically. The company has posted diversified double-digit revenue growth, a fast-growing Beauty & Cosmetics segment, and a transformative Indovida merger while on the charts, the stock is sitting near the apex of a multi-year symmetrical triangle pattern that has been building since 2021.
This article breaks down EPL’s latest fundamentals, technical setup, key support and resistance zones, and what these developments could mean for long-term investors tracking EPL share price.
EPL delivered 13% YoY revenue growth in FY26 to ₹4,763 crore, led by Beauty & Cosmetics (+30% YoY, now ~40% of revenue) and a recovering Oral Care segment (+10% YoY). The Indovida merger will create a combined entity with revenue of ~₹8,300 crore and EBITDA of ~₹1,750 crore, diversifying EPL beyond tubes into bottles, caps and rigid packaging. The balance sheet continues strengthening, with Net Debt/EBITDA down to 0.51x and ROCE at 18.7%. Technically, the stock is trading near the apex of a multi-year symmetrical triangle, with major resistance at ₹230–235 and strong support at ₹205–215 a decisive breakout in either direction now appears close.
Key Takeaways
Fundamental Analysis of EPL Share Price
1. Strong Double-Digit Revenue Growth Across Geographies
FY26 revenue increased 13% YoY to ₹4,763 crore. Q4 FY26 revenue grew 17.6% YoY, driven by all regions: Americas (+24%), EAP (+25%), Europe (+15%) and AMESA (+10%).
Equity Research Take: Growth is diversified instead of depending on one geography, and healthy global demand reduces regional business risk.
2. Beauty & Cosmetics Becoming the Main Growth Driver
Beauty & Cosmetics grew around 30% YoY and now contributes nearly 40% of total revenue, up from 37% last year marking the 4th consecutive quarter of 20%+ growth. Since Beauty tubes command higher margins than Oral Care, this shift brings better pricing power, higher EBITDA margins, and better overall profitability.
3. Oral Care Recovery Adds Second Growth Engine
Oral Care grew 10% YoY after weak demand last year, with improved demand across India and AMESA. Instead of relying only on Beauty, EPL now has both Beauty growth and Oral recovery working together, making revenue more stable.
4. Indovida Merger Is a Long-Term Value Creator
The merger will create a combined entity with revenue around ₹8,300 crore and EBITDA around ₹1,750 crore, with a stronger presence across Asia, Africa and Latin America. The portfolio expands from tubes into bottles, caps and rigid packaging, bringing cross-selling opportunities, better customer relationships, procurement synergies, higher cash flow generation, and better operating leverage.
Equity Research View: The merger transforms EPL into a diversified packaging company rather than only a tube manufacturer.
5. Strong Global Manufacturing Expansion
Major expansion projects include a commissioned Thailand manufacturing plant, capacity expansion across Beauty products, an innovation centre established in Mumbai, and consolidation of China operations into one efficient plant. Thailand is currently under customer validation and should contribute more from FY27 onward.
6. Margin Profile Remains Healthy Despite Cost Inflation
FY26 EBITDA Margin remained around 20%. Q4 margins declined due to higher polymer prices, freight inflation, shipping disruptions, and Rupee depreciation. However, gross margin improved and the premium product mix continued increasing a higher Beauty mix should gradually support margins over time.
7. Balance Sheet Becoming Stronger
| Metric | Value |
|---|---|
| Debt/Equity | Reduced to ~0.32x |
| Net Debt/EBITDA | Improved from 1.12x to 0.51x |
| ROCE | Improved to 18.7% |
| ROE | Improved to 16.3% |
| Interest Coverage | Improved to 5.3x |
Management is targeting ROCE above 25% by FY29.
Equity Research View: Financial quality continues to improve while leverage declines.
8. Cash Flow Quality Remains Strong
Operating Cash Flow is close to EBITDA, with CFO/EBITDA around 95%, indicating good cash conversion, lower working capital stress, and earnings backed by real cash generation. This supports future expansion, dividends, and debt reduction.
9. Strong Customer Base & Emerging Market Focus
Key global customers include Unilever, L’Oréal, and P&G. After the merger, around 75% of revenue will come from emerging markets, with around 90% of Indovida’s revenue already coming from fast-growing markets. Emerging markets generally offer faster volume growth, rising personal care consumption, and better long-term demand.
10. FY27–FY29 Growth Outlook Remains Strong
Growth drivers include Beauty & Cosmetics expansion, Oral Care recovery, Thailand plant ramp-up, Indovida merger synergies, premium product mix, sustainable packaging adoption, higher operating leverage, and cost optimisation initiatives.
Analyst forecasts (FY26–FY28):
| Metric | CAGR |
|---|---|
| Revenue | ~8% |
| EBITDA | ~9% |
| PAT | ~16% |
Technical Analysis of EPL Share Price
Multi-Year Symmetrical Triangle (Most Important Observation)
This is the biggest pattern visible on the chart. The stock has been making Lower Highs since 2021 and Higher Lows since 2022, forming a large Symmetrical Triangle a volatility contraction pattern. This means buyers are willing to buy at higher prices while sellers are accepting lower selling prices, and eventually one side wins. The stock is currently trading almost at the apex of the triangle, meaning a big move is getting closer.
Long-Term Trend Is Still Bullish
Despite the consolidation, the long-term trend has not broken. The 200 SMA is rising, price is above the 200 SMA, and long-term higher highs and higher lows remain intact.
Current Moving Averages:
| Moving Average | Level |
|---|---|
| 50 SMA | ~215 |
| 100 SMA | ~226 |
| 200 SMA | ~207 |
| Current Price | ₹222 |
Price is above the 50 SMA and 200 SMA, and only slightly below the 100 SMA. This is not bearish it is neutral-to-bullish.
200 SMA Acting as Dynamic Support
Every major correction since 2014 has respected the 200-week moving average. Even in 2022, price sharply bounced from that area, indicating long-term institutions are still accumulating on declines. Unless price closes below the 200 SMA, the structural uptrend remains intact.
Volume Behaviour Is Constructive
Volumes were huge during the 2020–2021 rally, and have gradually reduced since — exactly what happens during healthy consolidation. What you don’t want is huge selling volume every week, and that is absent. Instead, volume is drying up, which generally precedes expansion.
RSI Is Around 50 (Very Healthy)
Current RSI is around 50 neither overbought nor oversold. This means the stock has enough energy for a breakout in either direction, without the warning signs that would come with an RSI near 75 (overbought) or 25 (oversold).
Price Compression Is Increasing
The swings are becoming progressively smaller: from a move of 150 to 290, then 190 to 280, then 210 to 245, and now 215 to 230. Volatility is shrinking, which usually precedes an explosive movement like a spring, the more compressed it gets, the stronger the eventual release.
Risk-Reward Is Improving
Buying in the middle of consolidation usually gives poor reward, while buying near support gives excellent reward. The current position is closer to support than resistance, making risk manageable though fresh aggressive buying should ideally happen only after confirmation.
Chart Psychology
In 2021, everyone was excited and price became expensive, at which point smart money started distributing. After that, retail interest faded, and for almost 4 years, price has moved sideways. This long consolidation allows earnings to catch up, valuations to normalise, and weak hands to exit.
Support & Resistance Levels
| Level Type | Price Zone | Significance |
|---|---|---|
| Strong Support | ₹205–215 | Where the 200 SMA, rising trendline, previous swing highs, and multiple weekly reversals converge, making it a strong institutional support zone. |
| Major Resistance | ₹230–235 | Site of multiple prior swing highs; every rally has faced selling pressure near this zone so far. |
A weekly close below ₹205 would weaken the chart significantly, while only a decisive weekly breakout above ₹230–235 changes the entire picture.
Bullish & Bearish Scenarios
Bullish Scenario: A weekly close above ₹235–240, accompanied by strong volume, RSI above 60, and follow-through in the next week, could open target zones of ₹260, ₹285, and ₹310 potentially new all-time highs over time if supported by fundamentals.
Bearish Scenario: A weekly close below ₹205 would mean the triangle fails, with possible downside toward ₹190, ₹175, and ₹160.
Risks & Growth Drivers
Growth Drivers:
- Beauty & Cosmetics segment sustaining 20%+ growth for four consecutive quarters, now ~40% of revenue
- Indovida merger creating a combined ~₹8,300 crore revenue, ~₹1,750 crore EBITDA diversified packaging company
- Oral Care recovery adding a second, more stable growth engine
- Thailand plant ramp-up expected to contribute more meaningfully from FY27 onward
- ~75% of post-merger revenue coming from emerging markets, offering faster volume growth
- Continued balance sheet strengthening, with Net Debt/EBITDA down to 0.51x and a FY29 ROCE target above 25%
- Strong cash conversion (CFO/EBITDA ~95%) supporting expansion, dividends, and further deleveraging
Risks:
- Q4 margins were pressured by higher polymer prices, freight inflation, shipping disruptions, and Rupee depreciation
- The stock has been in a prolonged multi-year sideways consolidation since the 2021 peak, testing investor patience
- The technical setup is currently undecided the next big trend depends on which side of the ₹205–235 range the stock breaks
- A weekly close below ₹205 would weaken the chart significantly and could open downside toward ₹190, ₹175, and ₹160
Analyst View
Based on the fundamental data provided, EPL is executing a well-diversified growth strategy a fast-growing, higher-margin Beauty & Cosmetics business, a recovering Oral Care segment, and a transformative Indovida merger that broadens the company beyond tubes into a fuller packaging portfolio. Improving balance sheet metrics (Net Debt/EBITDA at 0.51x, ROCE at 18.7% with a FY29 target above 25%) and strong cash conversion further support the long-term investment case, according to the data reviewed.
From a technical standpoint, EPL presents one of the more distinctive setups among the stocks in this series: a multi-year symmetrical triangle nearing its apex, with shrinking volatility that historically precedes a significant directional move. The long-term trend remains intact above the 200 SMA, but the immediate direction will be determined by whether the stock closes decisively above ₹230–235 or below ₹205.